Test Price
2,800 AED✅ Home Collection Available
JAK2 Mutation Analysis (Exons 12, 14, 16) by Next-Generation Sequencing (NGS) in UAE | 2800 AED | 2026 DHA Guidelines
تحليل طفرة جين JAK2 (الإكسونات 12، 14، 16) بتقنية التسلسل الجيني من الجيل التالي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
This advanced molecular test precisely identifies JAK2 mutations in exons 12, 14 and 16 using NGS, delivering 99.9% diagnostic sensitivity. The service includes hospital-grade home collection, VIP phlebotomy, cold-chain transport under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139), and direct insurance billing verification via WhatsApp. Results are interpreted with expert post-test clinical guidance. Fully compliant with Federal Decree-Law No. 41 of 2024 (Art. 87), UAE CDS Law 2026 for minors, and UAE PDPL.
الملخص التنفيذي
يوفر تحليل طفرة جين JAK2 بتقنية التسلسل الجيني من الجيل التالي دقة تشخيصية تصل إلى 99.9% مع خدمات سحب منزلي معتمدة ونقل مبرّد وفق معيار ISO 9001:2015، واستشارة وراثية بعد النتيجة. جميع الإجراءات متوافقة مع القانون الاتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية الإماراتي.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview
The JAK2 Mutation Analysis by NGS precisely identifies somatic mutations in exons 12, 14, and 16 of the JAK2 gene, critical for diagnosing Philadelphia-negative myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. هذا التحليل الجيني المتقدم يوفر دقة عالية ويُستخدم لتوجيه العلاج وتقييم مخاطر التجلط.
| Feature | Our Test (NGS Exon 12,14,16) | Closest Alternative (Sanger / Limited Panel) |
|---|---|---|
| Precision | >99.9% sensitivity for low-frequency variants | ~95% sensitivity, may miss minor clones |
| Methodology | Next-Generation Sequencing (Illumina® platform), allele-specific analysis | Sanger sequencing or ARMS-PCR, limited exon coverage |
| Turnaround Time | 3–4 weeks, with integrated genetic counseling | 4–6 weeks, often without counseling support |
Physician Insight & Safety Protocol
"As a hematopathologist, I understand that facing a possible myeloproliferative neoplasm can be daunting. This test provides vital molecular evidence to confirm the diagnosis and tailor therapy, but results must be correlated with full blood counts and clinical symptoms. A negative JAK2 mutation does not rule out all MPNs; other driver mutations may be present."
— Dr. PRABHAKAR REDDY, DHA License: 61713011
Medication Warning: Do not discontinue any prescribed blood thinners, hydroxyurea, or chemotherapy without consulting your doctor. Abrupt cessation may increase thrombosis risk.
Exclusion Criteria & ER Red Flags
- Individuals under 18 years: UAE CDS Law 2026 mandates parental consent and a pre‑test genetic counseling session before sample collection.
- Recent blood transfusion (within 14 days) or severe hemolysis may compromise DNA quality; reschedule the draw.
- Pregnancy: genetic counseling advised; test may proceed but requires specialist referral and informed consent.
- Emergency Red Flags: Sudden severe headache, blurred vision, chest pain, or unilateral leg swelling could indicate acute thrombosis—seek immediate medical attention.
Patient FAQ & Clinical Guidance
What does the JAK2 NGS test detect, and why is it important?
The JAK2 NGS test detects mutations in exons 12, 14, and 16 to accurately diagnose myeloproliferative neoplasms and guide treatment. Mutations in JAK2, especially V617F (exon 14), are found in over 95% of polycythemia vera and 50-60% of essential thrombocythemia and primary myelofibrosis. The NGS method identifies both common and rare variants with high sensitivity, enabling precise classification and risk stratification for thrombotic events.
ما هي طفرة JAK2 وكيف يتم استخدام التحليل؟
يكتشف تحليل JAK2 بتقنية NGS الطفرات في الإكسونات 12 و14 و16 لتشخيص أورام التكاثر النخاعي وتوجيه العلاج. تعتبر هذه الطفرات أساسية في تصنيف كثرة الحمر الحقيقية وكثرة الصفيحات الأساسية والتليف النخاعي الأولي. توفر الخدمة في الإمارات دقة 99.9% مع استشارة وراثية بعد الفحص.
How should I prepare for the JAK2 blood test, and what are the sample requirements?
No fasting or medication changes are required; a simple blood draw or buccal swab is collected for optimal DNA extraction. Our home collection team uses ISO-certified cold chain transport to maintain sample integrity, and you can provide whole blood, extracted DNA, or a dried blood spot on an FTA card. A genetic counseling session will be arranged to review your pedigree and explain the implications.
Is the JAK2 test covered by insurance in the UAE?
Many UAE insurers cover JAK2 mutation testing when medically necessary; direct billing verification is available via WhatsApp. Our team contacts your insurer to confirm coverage for the 2800 AED, and we handle documentation for DHA-regulated facilities. For insurers requiring pre-authorization, we assist with the clinical justification letter.
ICD-10-CM 2026: D45 (Polycythemia vera, JAK2-positive), D47.3 (Essential thrombocythemia, JAK2-mutated), D47.1 (Primary myelofibrosis). LOINC: 82939-2 – JAK2 gene mutations found. Methodology: Targeted NGS (Illumina), ISO 9001:2015 Certified (INT/EGQ/2509DA/3139). DHA Facility License: 9834453. For home collection and counseling bookings, WhatsApp +971 54 548 8731.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians